iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Aurobindo Pharma hits new 52-week high as Telangana unit gets USFDA approval

20 Nov 2023 , 11:12 AM

Shares of Aurobindo Pharma gained more than 1% in early trade on November 20 to a new 52-week high of Rs 1,024.95 per piece after the United States Food and Drug Administration (USFDA) completed an examination with zero observations.

The USFDA performed a Pre-Approval Inspection (PAI) at APL Healthcare Ltd, a wholly-owned subsidiary of the business, at TSIIC Green Industrial Park, Pollepally Village in Telangana, Unit-I, and III, formulation production plant.

The inspection took place from November 13 to 17 and ended with zero observations and a designation of ‘No Action Indicated’ (NAI), according to the business.

Injectables under Eugia are expected to increase by double digits and reach $500 million, driving growth in the core business. The business has stated that it intends to introduce 40 goods during the following 12 months.

For the July-September quarter of the current fiscal year, the business recorded an 85 percent year-on-year increase in consolidated net profit to Rs 757 crore. Revenue was Rs 7,219.4 crore, up 25.7 percent from Rs 5,739.3 crore in the previous quarter.

At around 10.46 AM, Aurobindo Pharma was trading 0.98% higher at Rs 1,017.25 per piece, against the previous close of Rs 1,007.35 on NSE.

For feedback and suggestions, write to us at editorial@iifl.com

explored-media

Related Tags

  • Aurobindo Pharma
  • Aurobindo Pharma News
  • Aurobindo Pharma Stock
  • Aurobindo Pharma Updates
  • Aurobindo Pharma USFDA
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.